Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

To the Editor: Kopetz et al. (Oct. 24 issue)(1) found an overall survival benefit of triplet therapy (encorafenib, binimetinib, and cetuximab) as compared with control therapy (cetuximab with either irinotecan or FOLFIRI [folinic acid, fluorouracil, and irinotecan]) among patients with BRAF-mutated colorectal cancer. The trial also included a third group that received doublet therapy (encorafenib and cetuximab). Although the trial was not powered to compare the triplet-therapy group with the doublet-therapy group, a number of observations favor the doublet-therapy group. First, among more than 200 patients in each group, the median progression-free survival was similar in the doublet-therapy group and . . .